Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs LTC Properties Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while LTC Properties Inc trades at $40.09 (market cap $2.05B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.9× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.7% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LTC | |
|---|---|---|
Market Cap | $8.04B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $339.75 | $40.36 |
52-Week Low | $241.71 | $33.98 |
Enterprise Value | $7.85B | $2.90B |
Dividend Yield | — | 5.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
LTC Properties (LTC) trades at $39.67, up 2.08% today, with a bullish technical signal from moving averages and a P/E of 15.56. Revenue grew to $263M in 2025, with a net income margin of 39.09%, though recent quarters saw earnings misses. The company is expanding its SHOP portfolio, with acquisitions like the $73M purchase in July 2026, and maintains a monthly dividend of $0.19 per share.
Outlook is mixed: strong fundamentals and demographic trends support growth, but earnings volatility and high debt pose risks. Analysts are cautious, with 59% holding neutral ratings. Key catalysts include SHOP transition success, while risks involve interest rate sensitivity and execution challenges in acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
